This Week in Oncology — May 14, 2026

Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning major advances in treating central nervous system malignancies, new strategies for refining breast cancer therapy, and a look at emerging therapeutic platforms. Let's dive in.

We'll start in neuro-oncology, where several new papers explore novel treatment strategies for glioblastoma and managing brain metastases.

For decades, radiotherapy for glioblastoma has involved large radiation fields to account for microscopic disease spread. A new study in The Lancet Oncology challenges this paradigm [2]. The single-arm, phase 2 UNITED trial investigated an MRI-guided adaptive radiotherapy approach.

The Study Investigators treated 98 patients with newly diagnosed glioblastoma using an MR-Linac. They applied a tight 5-millimeter clinical target volume, much smaller than conventional margins, and used weekly MRI scans to adapt the treatment plan online.

Results The primary outcome was the rate of marginal failure, meaning tumor recurrence at the edge of the treatment field. At a median follow-up of over 14 months, the observed risk of marginal failure was only 4 percent, which was non-inferior to a historical control. The approach was safe, with no treatment-related deaths.

Discussion This study suggests that with advanced imaging and adaptation, we may be able to safely de-escalate radiation volumes in glioblastoma. The next step will be a randomized trial to see if this translates to better quality of life and reduced toxicity compared to standard large-margin radiotherapy.

While radiation remains a cornerstone, the search for effective systemic therapies continues. Two papers this week highlight promising immunotherapeutic approaches. First, in Science Translational Medicine, researchers identified a new target for CAR T-cell therapy in glioblastoma: the urokinase plasminogen activator receptor, or uPAR [7]. Through a multiomic analysis of patient-derived GBM cell lines, they found that uPAR was highly expressed, particularly in recurrent disease and on brain tumor-initiating cells. They then developed uPAR-specific CAR T-cells.

Key Findings These CAR T-cells showed potent antitumor activity in patient-derived xenograft models of recurrent glioblastoma. Interestingly, uPAR was also found on glioblastoma-associated macrophages, meaning the CAR T-cells could target both the tumor cells and key components of the immunosuppressive tumor microenvironment. This dual targeting could be a significant advantage.

Another immunotherapeutic strategy, personalized vaccines, was explored in a phase 1 trial published in Nature Cancer [9]. This study tested a DNA-based personalized neoantigen vaccine in nine patients with newly diagnosed, MGMT-unmethylated glioblastoma, a particularly difficult-to-treat subgroup.

Methods Following surgery and radiation, patients received the vaccine, which was personalized with up to 40 neoantigens identified from their tumor. The primary endpoints were safety and feasibility.

Results The vaccine was safe, with no serious adverse events. It successfully induced T-cell responses in nearly all patients who were not on dexamethasone. While it is a very small, early-phase study, the preliminary efficacy signals were encouraging. Median progression-free survival was 8.5 months and median overall survival was 16.3 months, with one patient still alive four years after surgery. These studies [7, 9] add to the growing body of evidence that immunotherapy can be harnessed against glioblastoma, but highlight different approaches—one targeting a common surface antigen with CAR-T, the other using a personalized vaccine to target unique neoantigens.

Shifting from primary brain tumors to brain metastases, a study in the Journal of Clinical Oncology addresses a common clinical dilemma in extensive-stage small cell lung cancer [4]. What is the best strategy for patients who experience brain-only progression after first-line therapy?

The Study This multicenter cohort study analyzed 203 such patients, comparing three second-line strategies: first, continuing the original systemic therapy plus brain radiotherapy; second, switching to a new systemic therapy plus brain radiotherapy; and third, switching systemic therapy alone.

Results After balancing for baseline characteristics, the results were clear. Continuing the original systemic therapy backbone and adding brain radiotherapy led to a significantly longer median overall survival of 14.7 months. This was superior to both switching systemic therapy plus radiotherapy, which had a median survival of 9.8 months, and switching therapy alone, at 10.2 months. The benefit of continuing the original regimen was most pronounced in patients who had received prior immunotherapy and had a longer initial progression-free survival.

Clinical Bottom Line For patients with extensive-stage small cell lung cancer whose disease is controlled systemically but progresses only in the brain, these data support a strategy of adding local brain-directed radiotherapy while continuing the effective systemic backbone, rather than switching to a new systemic agent.

Finally in our CNS section, a sobering case report from The New England Journal of Medicine serves as an important reminder about the long-term safety of novel therapeutics [6]. It details the case of a 5-year-old boy who developed a neuroepithelial tumor four years after receiving intracisternal gene therapy for mucopolysaccharidosis type I. The therapy used an adeno-associated virus, or AAV, vector. While AAV vectors are considered to be predominantly non-integrating, molecular analysis of the tumor revealed clonal integration of the AAV vector into the genome, leading to the expression of a fusion transcript driving the cancer. This is a rare event, but it highlights the potential for insertional oncogenesis with AAV-based therapies, a critical consideration as these platforms are explored for various diseases, including cancer.

Next, we turn to breast cancer, with three papers that refine our approaches to radiotherapy, chemotherapy selection, and biomarker discovery.

First, The Lancet Oncology published the highly anticipated 10-year results of the FAST-Forward trial [1]. This study sought to establish a one-week course of adjuvant breast radiotherapy that is as safe and effective as the standard three-week schedule.

The Study The trial randomized over 4,000 patients with early-stage breast cancer after surgery to one of three regimens: the standard 40 Gray in 15 fractions over three weeks, or one of two ultra-hypofractionated schedules delivered over one week—either 27 Gray or 26 Gray, both in five fractions.

10-Year Results At a median follow-up of 10 years, the 26 Gray schedule proved its durability. The 10-year rate of ipsilateral breast recurrence was just 2.1 percent in the 26 Gray group, compared to 3.6 percent in the standard 40 Gray group, confirming non-inferiority. Importantly, the rates of moderate or marked long-term normal tissue effects were similar between the 26 Gray and 40 Gray arms. The 27 Gray schedule also had excellent efficacy but was associated with slightly higher rates of normal tissue effects.

Substudy The publication also includes 5-year data from a substudy of patients requiring axillary nodal radiation, which showed reassuring efficacy for the 26 Gray schedule in this setting as well.

Conclusions These long-term data solidify 26 Gray in five fractions over one week as a standard of care for adjuvant whole breast or chest wall radiotherapy, offering a more convenient and resource-sparing option for patients.

While radiotherapy is a local treatment, selecting the right systemic therapy is paramount, especially in triple-negative breast cancer, or TNBC. A landmark paper in Nature used single-cell and spatial transcriptomics to dissect the tumor microenvironment of TNBC and understand why some tumors respond to chemotherapy while others do not [5]. Investigators analyzed pretreatment tissue from 101 patients who went on to receive neoadjuvant chemotherapy. They identified four distinct patient archetypes based on cancer cell gene expression, and eight different cellular 'ecotypes' based on the co-occurrence of cancer cells and various immune and stromal cells.

Key Insights Contrary to many previous studies that focused heavily on T-cells, this analysis revealed the critical importance of macrophage subtypes and specific cancer-cell programs. Good response to chemotherapy was associated with cancer cells that had high activity in interferon signaling, HLA expression, and cell cycle pathways. The presence of specific macrophage subtypes was also predictive. This work provides a new, high-resolution map of the TNBC ecosystem and suggests that biomarkers for chemo-response may lie not just in T-cell infiltration, but in a complex interplay between cancer cells and macrophages.

Building on this theme of using spatial information for biomarker discovery, a paper in Cell introduces a powerful new computational tool called Path2Space [10]. Spatial transcriptomics is a revolutionary technology, but its high cost limits its use in large clinical cohorts. Path2Space is a deep-learning model that addresses this limitation. It is trained to predict spatial gene expression directly from standard, inexpensive hematoxylin and eosin, or H&E, pathology slides.

The Model Trained on a large dataset of breast cancer spatial transcriptomics, the model can robustly predict the spatial expression of thousands of genes from just the H&E image. It can accurately infer the abundance and location of different cell types within the tumor microenvironment.

Clinical Application When applied to over 900 breast cancer cases from The Cancer Genome Atlas, the AI-derived spatial landscapes were more accurate at predicting patient response to chemotherapy and trastuzumab than conventional biomarkers derived from costly bulk sequencing. This offers a scalable and cost-effective way to unlock spatial biology from routine pathology slides, potentially accelerating biomarker discovery and clinical translation.

Finally, we will look at two papers that explore broader therapeutic concepts with wide-ranging implications for oncology.

First, a comprehensive review in Cell provides a state-of-the-art overview of antibody-drug conjugates, or ADCs [3]. This class of drugs is one of the fastest-growing areas in cancer therapy, with approvals across numerous solid and hematologic malignancies. The review synthesizes the complex biology of ADCs—from the antibody target and linker chemistry to the cytotoxic payload—and discusses the clinical progress made. It highlights the key challenges and opportunities as these agents move into earlier lines of therapy and are tested in combination regimens. For anyone looking to get up to speed on this crucial drug class, this review is an excellent resource, emphasizing the growing need for careful patient selection and proactive toxicity management.

Our last paper, from Science Translational Medicine, explores a fascinating biological mechanism that, while studied here in lung fibrosis, has profound implications for cancer biology and therapy [8]. The study investigates why senescent cells, which can drive disease, are not cleared by the immune system. Researchers focused on pulmonary fibrosis, where senescent fibroblasts are thought to drive disease progression. Using single-cell analysis, they found that natural killer, or NK, cells in fibrotic lungs were exhausted.

The Mechanism The key finding was the identification of an immune checkpoint axis responsible for this. The senescent fibroblasts expressed high levels of HLA-E, which is the ligand for the inhibitory receptor NKG2A on NK cells. This interaction effectively put the brakes on the NK cells, preventing them from clearing the senescent fibroblasts. Spatial analysis showed these HLA-E-positive fibroblasts creating an 'immune-privileged niche'.

Therapeutic Implications Crucially, blocking this interaction with an NKG2A inhibitor, such as monalizumab, restored NK cell function and led to the clearance of senescent fibroblasts and resolution of fibrosis in a mouse model. Senescent cells are known to contribute to cancer progression and therapy resistance, and immune evasion is a hallmark of cancer. This work uncovers a specific mechanism of NK cell evasion by senescent cells and points to NKG2A blockade as a promising strategy to eliminate them—a concept highly relevant to developing novel cancer immunotherapies.

If you only have time for one paper this week, make it the 10-year update of the FAST-Forward trial in The Lancet Oncology [1]. This paper provides the definitive, long-term evidence supporting a one-week course of adjuvant breast radiotherapy. It’s a practice-affirming and practice-changing study that improves convenience and value for a huge population of patients with early-stage breast cancer.

Here are the key takeaways from this week in Oncology.

First, for early-stage breast cancer, a one-week course of adjuvant radiotherapy with 26 Gray in 5 fractions is a safe and effective standard of care, with 10-year outcomes non-inferior to a conventional three-week schedule [1].

Second, in extensive-stage small cell lung cancer with brain-only progression, continuing the effective first-line systemic therapy and adding brain radiotherapy is superior to switching systemic agents [4].

Third, for glioblastoma, several promising avenues are being explored. MRI-guided adaptive radiotherapy may allow for smaller, safer radiation fields [2], while new immunotherapies like uPAR-targeted CAR T-cells [7] and personalized neoantigen vaccines [9] show early promise.

Fourth, new high-resolution and computational tools are changing our understanding of the tumor microenvironment. Single-cell analysis in TNBC points to macrophages as key players in chemo-response [5], and AI models can now predict spatial transcriptomics from standard pathology slides, unlocking new biomarkers [10].

Finally, a newly identified immune checkpoint, the HLA-E/NKG2A axis, allows senescent cells to evade NK cell clearance, and blocking it represents a novel therapeutic strategy with potential applications in oncology [8].

That's your roundup for This Week in Oncology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.